Evidence map›Paper›PMID 39390828›Full record

ReviewCurrent drug delivery2026

Nanoparticle-Mediated Transcytosis in Tumor Drug Delivery: Mechanisms, Categories, and Novel Applications.

Nakaooh Doaa, Signa Lon Rolande Detorgma, Kaiyun Yang, Rajae Salama, Wenli Zhang

Erratum issuedAbstract readReview
PubMed Publisher
In one paragraph

Review in Current drug delivery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Nanomedicine for Glioblastoma Therapy: Novel Insights and Future Perspectives.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology
    Review
  6. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Nakaooh DoaaDepartment of Pharmaceutics, China Pharmaceutical University, Nanjing210009, PR China.
Signa Lon Rolande DetorgmaDepartment of Pharmaceutics, China Pharmaceutical University, Nanjing210009, PR China.
Kaiyun YangSchool of Pharmacy, University of Auckland, Private Bag 92019, Auckland, New Zealand.
Rajae SalamaDepartment of Pharmaceutics, China Pharmaceutical University, Nanjing210009, PR China.
Wenli ZhangDepartment of Pharmaceutics, China Pharmaceutical University, Nanjing210009, PR China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The development of nanotechnology-based drug delivery systems has been extensively investigated across various therapies, leading to the creation of numerous nanomedicines for clinical use. However, these nanomedicines have yet to achieve the anticipated therapeutic efficacy in clinical settings, highlighting the urgent need for further research in this area. A primary challenge in nanomedicine research lies in ensuring that nanoparticles and therapeutic agents can effectively penetrate and accumulate within tumors. The enhanced permeability and retention (EPR) effect has been previously explored as a means to enhance drug delivery to tumors, but recent findings have revealed its limitations, including variable responses, restricted penetration, clearance by the reticuloendothelial system, and non-specific accumulation. As an alternative approach, transcytosis has been explored for delivering drugs to specific organs or tissues, potentially bypassing some of the constraints of the EPR effect. For example, nanoparticles can be guided through barriers by targeting specific receptors on cell surfaces or by utilizing a different charge compared to tumor cells' surfaces. Therefore, this article explores transcytosis, including adsorptive, receptor-mediated, and cell-mediated subtypes, all of which have demonstrated promising results and offer potential solutions to enhance the effectiveness of nanomedicine delivery for cancer therapy.

Indexed as

Antineoplastic AgentsDrug Delivery SystemsNanoparticlesNeoplasmsTranscytosisAnimalsHumansNanomedicineAntineoplastic Agentsadsorptive-mediated transcytosiscell-- mediated transcytosisdrug delivery systemenhanced permeability and retention effect.receptor-mediated transcytosistranscytosisTumor

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.